Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy
- Conditions
- Toxic Maculopathy
- Interventions
- Procedure: Composite Examination
- Registration Number
- NCT02550964
- Lead Sponsor
- Asan Medical Center
- Brief Summary
The purpose of this study is to evaluate the incidence and risk factor of toxic maculopathy who treated with hydroxychloroquine or chloroquine due to their autoimmune disease such as rheumatoid arthritis or systemic lupus erythematosus. Total 5-year of the study periods, the investigators will screen these patients by baseline examination (Fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography) and observe with same examination for every year.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 124
Inclusion Criteria
- Patient who treated with HCQ or CQ due to autoimmune diseases such as RA, SLE
- Patient who did not previously diagnosed with HCQ/CQ toxic retinopathy
Read More
Exclusion Criteria
- Aged less than 19 years
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description HCQ/CQ Composite Examination Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.
- Primary Outcome Measures
Name Time Method Incidence of toxic maculopathy associated with HCQ or CQ 1 years
- Secondary Outcome Measures
Name Time Method Risk factor of HCQ/CQ retinopathy 5 years Characteristics and type of HCQ/CQ retinopathy (parafoveal or pericentral retinopathy) 5 years Progression of retinopathy after drug cessation 1 years
Trial Locations
- Locations (1)
Asan Medical Center
🇰🇷Seoul, Korea, Republic of